1. Home
  2. HDB vs GILD Comparison

HDB vs GILD Comparison

Compare HDB & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HDB
  • GILD
  • Stock Information
  • Founded
  • HDB 1994
  • GILD 1987
  • Country
  • HDB India
  • GILD United States
  • Employees
  • HDB N/A
  • GILD N/A
  • Industry
  • HDB Commercial Banks
  • GILD Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HDB Finance
  • GILD Health Care
  • Exchange
  • HDB Nasdaq
  • GILD Nasdaq
  • Market Cap
  • HDB 178.1B
  • GILD 145.4B
  • IPO Year
  • HDB N/A
  • GILD 1992
  • Fundamental
  • Price
  • HDB $37.30
  • GILD $121.65
  • Analyst Decision
  • HDB
  • GILD Buy
  • Analyst Count
  • HDB 0
  • GILD 21
  • Target Price
  • HDB N/A
  • GILD $118.45
  • AVG Volume (30 Days)
  • HDB 3.6M
  • GILD 7.8M
  • Earning Date
  • HDB 10-18-2025
  • GILD 10-30-2025
  • Dividend Yield
  • HDB 1.04%
  • GILD 2.60%
  • EPS Growth
  • HDB N/A
  • GILD 496.80
  • EPS
  • HDB 0.53
  • GILD 5.01
  • Revenue
  • HDB $30,210,861,338.00
  • GILD $28,863,000,000.00
  • Revenue This Year
  • HDB N/A
  • GILD $2.08
  • Revenue Next Year
  • HDB $11.45
  • GILD $3.96
  • P/E Ratio
  • HDB $21.60
  • GILD $24.24
  • Revenue Growth
  • HDB 2.23
  • GILD 3.81
  • 52 Week Low
  • HDB $28.89
  • GILD $85.60
  • 52 Week High
  • HDB $39.81
  • GILD $124.61
  • Technical
  • Relative Strength Index (RSI)
  • HDB 35.14
  • GILD 63.61
  • Support Level
  • HDB $34.68
  • GILD $115.80
  • Resistance Level
  • HDB $36.97
  • GILD $124.61
  • Average True Range (ATR)
  • HDB 0.61
  • GILD 3.12
  • MACD
  • HDB 1.60
  • GILD 0.80
  • Stochastic Oscillator
  • HDB 95.92
  • GILD 80.18

About HDB HDFC Bank Limited

HDFC Bank Ltd is an Indian bank. It operates in the following segments: Treasury, Retail banking, Wholesale banking, and Other banking business. The maximum revenue for the company is generated from its Retail banking segment, which serves retail customers through its branch network and other channels. This segment raises customer deposits and provides loans and other services to customers using different product groups. Its other operations include providing wholesale banking services to corporates, government entities, and other enterprises, generating income from its treasury operations, and performing para-banking activities such as offering credit cards, debit cards, etc. Geographically, the company generates a majority of its revenue from its operations in India.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: